• Profile
Close

A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally-administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis

American Journal of Obstetrics and Gynecology Mar 16, 2018

Brand SR, et al. - In women with recurrent vulvovaginal candidiasis, the efficacy and safety of 4 dosing regimens of oral VT-1161 compared to placebo were evaluated. Researchers recognized VT-1161 to be efficacious and safe in treating these patients. In this work, VT-1161 was observed to be well tolerated, with a low incidence of adverse events.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay